Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Daily Feeds
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
Viridian Therapeutics (VRDN)
NASDAQ:VRDN
Holding VRDN?
Track your performance easily
VRDN Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$11.40 - $27.20
Previous Close$20.14
Volume1.83M
Average Volume (3M)1.49M
Market Cap
$1.60B
Enterprise Value$1.06B
Total Cash (Recent Filing)$552.92M
Total Debt (Recent Filing)$20.52M
Price to Earnings (P/E)―
Beta2.15
Next Earnings
May 07, 2025EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-4.31
Shares Outstanding79,212,747
10 Day Avg. Volume1,415,060
30 Day Avg. Volume1,487,477
Standard Deviation0.42
R-Squared0.02
Alpha0.05
Financial Highlights & Ratios
Price to Book (P/B)2.47
Price to Sales (P/S)5676.04
Price to Cash Flow (P/CF)-6.30
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/Revenue3.52K
Enterprise Value/Gross Profit3.39K
Enterprise Value/Ebitda-4.25
Forecast
1Y Price Target
$40.67Price Target Upside101.94% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering15
Viridian Therapeutics News
PremiumCompany Announcements
Viridian Therapeutics Achieves Milestone in Phase 3 Trial
Bulls Say, Bears Say
Bulls Say
Clinical TrialsThe Phase 3 THRIVE-2 study for veligrotug in thyroid eye disease is on track, potentially enabling a BLA submission and FDA approval.
Competitive AdvantageVeligrtug has the potential to displace Tepezza as the leader in treating TED, noting that product achieved $488M sales in 3Q, a minor increase compared to 2Q's $479M sales.
Financial StabilityViridian reported finishing the period with $753.2M in cash, cash equivalents, and short-term investments, which is expected to fund operations into H2 2027.
Bears Say
CompetitionEntering the already crowded FcRn space is a big investment for Viridian and the onus will be on Viridian to demonstrate differentiation.
Product ApprovalNone of Viridian's assets is approved, and payers may not be willing to reimburse Viridian's products.
Tolerability And EfficacySince hearing impairment is an on-target AE of IGF-1R antagonists, it's unlikely that VRDN-001 can deliver both superior efficacy and better tolerability, unless the lower drug volume (and exposure) leads to tolerability benefits.
---
Ownership Overview
4.38% Insiders
19.92% Mutual Funds
60.26% Other Institutional Investors
4.55% Public Companies and
Individual Investors
Risk Analysis
Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
VRDN FAQ
What was Viridian Therapeutics’s price range in the past 12 months?
Viridian Therapeutics lowest stock price was $11.40 and its highest was $27.20 in the past 12 months.
What is Viridian Therapeutics’s market cap?
Currently, no data Available
When is Viridian Therapeutics’s upcoming earnings report date?
Viridian Therapeutics’s upcoming earnings report date is May 07, 2025 which is in 141 days.
How were Viridian Therapeutics’s earnings last quarter?
Viridian Therapeutics released its earnings results on Nov 12, 2024. The company reported -$1.15 earnings per share for the quarter, missing the consensus estimate of -$1.057 by -$0.093.
Is Viridian Therapeutics overvalued?
According to Wall Street analysts Viridian Therapeutics’s price is currently Undervalued.
Does Viridian Therapeutics pay dividends?
Viridian Therapeutics does not currently pay dividends.
What is Viridian Therapeutics’s EPS estimate?
Viridian Therapeutics’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Viridian Therapeutics have?
Viridian Therapeutics has 79,212,746 shares outstanding.
What happened to Viridian Therapeutics’s price movement after its last earnings report?
Viridian Therapeutics reported an EPS of -$1.15 in its last earnings report, missing expectations of -$1.057. Following the earnings report the stock price went down -12.758%.
Which hedge fund is a major shareholder of Viridian Therapeutics?
Among the largest hedge funds holding Viridian Therapeutics’s share is Maverick Capital ltd. It holds Viridian Therapeutics’s shares valued at 75M.
---
Viridian Therapeutics Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$40.67 (101.94% Upside)
$40.67 (101.94% Upside)
Blogger Sentiment
Bullish
VRDN Sentiment 100%
Sector Average 72%
Sector Average 72%
Hedge Fund Trend
Increased
By 38.0 Shares
Last Quarter.
Last Quarter.
Insider Transactions
Bought Shares
Worth $30.5M over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Neutral
Last 7 Days ▲ 0.2%
Last 30 Days ▼ 0.3%
Last 30 Days ▼ 0.3%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
26.03%
12-Months-Change
Fundamentals
Return on Equity
-51.88%
Trailing 12-Months
Asset Growth
134.79%
Trailing 12-Months
Company Description
Viridian Therapeutics
Miragen Therapeutics, Inc. is a clinical stage biopharmaceutical company, which engages in the development of proprietary RNA-targeted therapeutics. Its product pipelines include MRG-106 that focuses on the treatment of blood cancer; and MRG-201 deals with the treatment of pathological fibrosis. The company was founded by William S. Marshall and Bruce L. Booth in February 2006 and is headquartered in Boulder, CO.
---
VRDN Company Deck
---
VRDN Earnings Call
Q1 2024
0:00 / 0:00
---
VRDN Stock 12 Month Forecast
Average Price Target
$40.67
▲(101.94% Upside)
Technical Analysis
Best Analysts Covering VRDN
1 Year
1 Year Success Rate
23/36 ratings generated profit
1 Year Average Return
+11.66%
reiterated a buy rating last month
Copying Laura Chico's trades and holding each position for 1 Year would result in 63.89% of your transactions generating a profit, with an average return of +11.66% per trade.
---